Analyst Activity – Cantor Fitzgerald Initiates Coverage On Cytokinetics (NASDAQ:CYTK) With a Overweight
Today, Cantor Fitzgerald initiated coverage on kmspico 10.0.4 activator free download (NASDAQ:CYTK) with a Overweight.
There are 8 buy ratings on the stock.
The current consensus rating on Cytokinetics (NASDAQ:CYTK) is Buy (Score: 3.00) with a consensus target price of $17.86 per share, a potential 54.61% upside.
Some recent analyst ratings include
12/16/2016-Cantor Fitzgerald initiated coverage with a Overweight rating.
12/13/2016-Piper Jaffray Cos. Reiterated Rating of Overweight.
12/1/2016-JMP Securities Reiterated Rating of Buy.
10/31/2016-Cowen and Company Reiterated Rating of Outperform.
9/1/2016-Needham & Company LLC Reiterated Rating of Buy.
Dividend information for Cytokinetics (NASDAQ:CYTK)
. Recent Insider Trading Activity For Cytokinetics (NASDAQ:CYTK) Cytokinetics (NASDAQ:CYTK) has insider ownership of 5.10% and institutional ownership of 66.25%.
On 8/31/2015 L Patrick Gage, Director, bought 1,000 with an average share price of $6.95 per share and the total transaction amounting to $6,950.00.
On 8/20/2015 L Patrick Gage, Director, bought 10,000 with an average share price of $6.55 per share and the total transaction amounting to $65,500.00.
On 5/6/2015 L Patrick Gage, Director, bought 10,000 with an average share price of $5.71 per share and the total transaction amounting to $57,100.00.
On 3/11/2015 Andrew A Wolff, CMO, sold 21,875 with an average share price of $7.80 per share and the total transaction amounting to $170,625.00.
On 12/30/2014 Fady Ibraham Malik, SVP, sold 21,630 with an average share price of $6.73 per share and the total transaction amounting to $145,569.90.
On 5/9/2014 L Patrick Gage, Director, bought 10,850 with an average share price of $4.09 per share and the total transaction amounting to $44,376.50.
About Cytokinetics (NASDAQ:CYTK) Cytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its lead drug candidate from its skeletal muscle contractility program, tirasemtiv, is a skeletal muscle troponin activator. The Company is developing CK-2127107, a skeletal muscle troponin activator. The Company has conducted approximately five Phase I clinical trials of CK-2127107. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is a cardiac muscle myosin activator. COSMIC-HF is a Phase II, double-blind, randomized, placebo-controlled, multicenter, clinical trial designed to assess the pharmacokinetics and tolerability of omecamtiv mecarbil dosed orally in patients with heart failure and left ventricular systolic dysfunction.
Recent Trading Activity for Cytokinetics (NASDAQ:CYTK) Shares of Cytokinetics closed the previous trading session at 11.55 0.00 0.00% with 310,366 shares trading hands\
via source:http://marketexclusive.com/analyst-activity-cantor-fitzgerald-initiates-coverage-on-cytokinetics-nasdaqcytk-with-a-overweight/47073/